Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about Longeveron
Recent news which mentions Longeveron
Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results
February 07, 2024
Tickers
LGVN
Tags
LGVN
Biotech
Market News
From
Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
December 05, 2023
Tickers
LGVN
Tags
Benzinga
Penny Stocks
Market News
From
Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
December 05, 2023
Tickers
LGVN
Tags
Benzinga
Penny Stocks
Market News
From
Benzinga
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
October 23, 2023
Tickers
LGVN
Tags
LGVN
Biotech
Market News
From
Benzinga
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
October 13, 2023
Tickers
LGVN
Tags
Market News
Interview
LGVN
From
Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
Tickers
AMGN
LGVN
MRNA
Tags
Longeveron
General
Health Care
From
Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
Tickers
ABOS
BIIB
LGVN
TLSA
Tags
General
Partner Content
Longeveron
From
Benzinga
Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases
August 07, 2023
Tickers
LGVN
Tags
Benzinga
General
Longeveron
From
Benzinga
Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
August 07, 2023
Tickers
AMGN
LGVN
LLY
Tags
News
LGVN
Biotech
From
Benzinga
Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS
July 11, 2023
Tickers
LGVN
Tags
LGVN
Biotech
Market News
From
Benzinga
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes?
June 28, 2023
Tickers
LGVN
Tags
Market News
Partner Content
LGVN
From
Benzinga
Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty
April 20, 2023
Tickers
LGVN
Tags
General
M&A
Longeveron
From
Benzinga
LGVN: Updating Model Following 2Q Results
August 17, 2022
Tags
Market News
Partner Content
Analyst Ratings
From
Benzinga
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
August 09, 2022
Tickers
ALZN
BIIB
LGVN
SLDB
Tags
Partner Content
SLDB
General
From
Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
August 02, 2022
Tickers
ANVS
LGVN
LLY
TECH
Tags
Tech
Market News
Benzinga
From
Benzinga
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
July 28, 2022
Tickers
BMY
LGVN
Tags
BMY
Benzinga
General
From
Benzinga
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
June 15, 2022
Tickers
LGVN
SAVA
STAB
Tags
STAB
Partner Content
General
From
Benzinga
Longeveron Partners With US Department Of Veterans Affairs For Its Phase 2 Alzheimer's Trial
April 18, 2022
Tickers
LGVN
Tags
Longeveron
General
Benzinga
From
Benzinga
Healthspan, Not Lifespan Should Be the Focus of Anti-Aging Research, Says Longeveron
March 30, 2022
Tickers
AMZN
LGVN
UBX
Tags
UBX
Market News
Benzinga
From
Benzinga
Longeveron Announces Fourth Quarter And Full Year 2021 Financial Results And Operational Progress
March 14, 2022
Tickers
LGVN
Tags
Market News
Benzinga
Press Releases
From
Benzinga
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
December 06, 2021
Tickers
LGVN
Tags
Market News
Benzinga
Partner Content
From
Benzinga
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment
October 04, 2021
Tickers
LGVN
Tags
Penny Stocks
Longeveron
General
From
Benzinga
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
September 29, 2021
Tickers
LGVN
Tags
Longeveron
Health Care
General
From
Benzinga
Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron
September 15, 2021
Tickers
JNJ
LGVN
MRN
PFE
Tags
Market News
PFE
Benzinga
From
Benzinga
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
September 09, 2021
Tickers
LGVN
Tags
General
Benzinga
Penny Stocks
From
Benzinga
Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval
July 07, 2021
Tags
Health Care
General
Benzinga
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.